Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | CHUK | O15111 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | TOP1 | P11387 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14339454 | 0.96 | MAPT (0.47) | SMN1; SMN2CHUKKDM4EALDH1A1HPGD | |
| SCHEMBL2222493 | 0.86 | MAPT (0.47) | SMN1; SMN2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL998491 | 0.78 | NISCH (0.61) | SMN1; SMN2CHUKKDM4EALDH1A1HPGD | |
| SCHEMBL13463193 | 0.76 | CHUK (0.43) | SMN1; SMN2CHUKKDM4EALDH1A1HPGD | |
| SCHEMBL24101498 | 0.76 | HTR1D (0.40) | SMN1; SMN2CHUKKDM4EALDH1A1HPGD | |
| SCHEMBL24101500 | 0.76 | HTR1D (0.40) | SMN1; SMN2CHUKKDM4EALDH1A1HPGD | |
| SCHEMBL24101860 | 0.76 | HTR1D (0.40) | SMN1; SMN2CHUKKDM4EALDH1A1HPGD | |
| SCHEMBL24408185 | 0.74 | NR2E1 (0.64) | SMN1; SMN2CHUKKDM4EALDH1A1HPGD | |
| SCHEMBL3715769 | 0.74 | CHRNA7 (0.64) | KDM4EALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL30160092 | 0.73 | KDM4E (0.73) | SMN1; SMN2KDM4EALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0217737-B1 | TETRAHYDRO-BETA-CARBOLINES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-08-14 | — | — | EP | claimed |
| US-4855295-A | Tetrahydro-beta-carbolines, and their use as drugs | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | claimed |
| JP-62181278-A | — | — | None | — | — | JP | disclosed |
| US-20180148446-A1 | PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-31 | — | — | US | disclosed |
| US-20180148446-A1 | PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | TAKEDA PHARMACEUTICALS CO (JP) | 2018-05-31 | — | — | US | disclosed |
| WO-2011084439-A1 | TETRAHYDROCARBOLINE DERIVATIVES AS EG5 INHIBITORS | SANOFI (FR) | 2011-07-14 | — | — | WO | disclosed |
| US-20070293532-A1 | Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use | TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1787991-A1 | PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2007-05-23 | — | — | EP | disclosed |
| EP-0588500-B1 | 3-Oxadiazolyl-1,6-naphthyridine derivatives with affinity for benzodiazepine receptors | DAINIPPON PHARMACEUTICAL CO (JP) | 1998-11-04 | — | — | EP | disclosed |
| US-5550118-A | THROMBOXANE SYNTHETASE INHIBITORS, ANTICOAGULANTS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| US-5484793-A | NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS; ALZHEIMER*S DISEASE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1996-01-16 | — | — | US | disclosed |
| EP-0665227-A1 | Polyhydronorharman synthase inhibitors | ELI LILLY AND COMPANY (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0217737-B1 | TETRAHYDRO-BETA-CARBOLINES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-08-14 | — | — | EP | disclosed |
| US-4855295-A | Tetrahydro-beta-carbolines, and their use as drugs | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | disclosed |
| US-4855295-A | Tetrahydro-beta-carbolines, and their use as drugs | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | disclosed |
| JP-S62181278-A | 5, 6, 7, 8-TETRAHYDRO-BETA-CARBOLINE DERIVATIVE AND DRUG CONTAINING THE SAME | SCHERING AG | 1987-08-08 | — | — | JP | disclosed |
| EP-0217737-A2 | Tetrahydro-beta-carbolines, process for their preparation and their use as medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 1987-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148446-A1 | PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE | PGA5, ATP6AP1, PPA1 | SMN1; SMN2 3534/4885CHUK 826/4885KDM4E 686/4885 |
| US-20070293532-A1 | Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use | PGA5, ATP6AP1, PPA1 | SMN1; SMN2 3534/4885CHUK 826/4885KDM4E 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.